[AF] WHO Pharmaceuticals Newsletter No. 4, 2005

[Martín Cañás]

Estimadas y estimados 
esta disponible el WHO Pharmaceuticals Newsletter No. 4, 2005
contenido
Regulatory Matters

Amfetamine -- Reintroduced with revised prescribing and patient information ............................... 1
Atomoxetine -- Risk of suicidal thoughts......................................................................... 1
Bacitracin, Fusafungine, Gramicidin, Tyrothricin -- Locally administered products withdrawn ...... 2
Cetuximab -- Recommendations for electrolyte monitoring..................................................... 2
Duloxetine -- Reports of adverse hepatic effects ................................................................ 2
Fentanyl transdermal system -- Labels updated for safe and appropriate use............................ 2
Hexavac -- Suspended due to concerns about long-term effects against hepatitis B.......................... 3
Medroxyprogesterone -- Loss of bone marrow density ....................................................... 3
Meloxicam -- Juvenile rheumatoid arthritis indication: label updated .......................................... 3
Nabumetone -- Stronger labelling for renal effects.............................................................. 4
Non-selective NSAIDs -- No changes to current prescribing practice........................................ 4
Paroxetine -- Potential risk in pregnancy .......................................................................... 4
Thioridazine -- Sale discontinued in Canada ..................................................................... 5


Safety of Medicines


Anti-TNF alpha products -- New measures to prevent activation of latent tuberculosis ................... 6
Beta-2 agonists -- Increased risks of asthma-related deaths................................................... 6
Cabergoline -- Use linked to gambling............................................................................ 6
Codeine & hydrocodeine -- Akathisia with long-term use.................................................... 6
Ezetimibe -- Reports of muscle pain............................................................................... 7
Hydromorphone -- Co-ingestion with alcohol harmful.......................................................... 7
Ibuprofen -- Reports of Stevens-Johnson syndrome............................................................. 7
Isotretinoin -- Strengthened risk management programme .................................................... 8
Trastuzumab -- Addition to chemotherapy increases toxicity .................................................. 8
Vinca alkaloids -- Intrathecal administration reported........................................................... 8
Feature
Twenty-eighth Annual Meeting of Representatives of the National Centres participating in the WHO
Programme for International Drug Monitoring: Observations from Working Group Exercises...........10


en la siguiente direccion
http://www.who.int/entity/medicines/publications/pn2005_4.pdf

Saludos,
Martín

Martin Cañás
GAPURMED La Plata (Argentina)
macanas en netverk.com.ar
------------ próxima parte ------------
Se ha borrado un adjunto en formato HTML...
URL: <http://listas.uninet.edu/pipermail/af/attachments/20051104/2561e321/attachment.htm>